Sodium phenylbutyrate in Huntington's disease: A dose-finding study

Penelope (Penny) Hogarth, Luca Lovrecic, Dimitri Krainc

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose-finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose-escalation/de-escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose-response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well-tolerated in human HD.

Original languageEnglish (US)
Pages (from-to)1962-1964
Number of pages3
JournalMovement Disorders
Volume22
Issue number13
DOIs
StatePublished - Oct 15 2007

Fingerprint

Huntington Disease
Confusion
Histone Deacetylase Inhibitors
Maximum Tolerated Dose
Dizziness
Acetylation
Gait
Histones
Vomiting
Animal Models
Phenotype
Safety
Gene Expression
4-phenylbutyric acid

Keywords

  • Histone deacetylase inhibitor
  • Huntington's disease
  • Sodium phenylbutyrate

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Sodium phenylbutyrate in Huntington's disease : A dose-finding study. / Hogarth, Penelope (Penny); Lovrecic, Luca; Krainc, Dimitri.

In: Movement Disorders, Vol. 22, No. 13, 15.10.2007, p. 1962-1964.

Research output: Contribution to journalArticle

Hogarth, Penelope (Penny) ; Lovrecic, Luca ; Krainc, Dimitri. / Sodium phenylbutyrate in Huntington's disease : A dose-finding study. In: Movement Disorders. 2007 ; Vol. 22, No. 13. pp. 1962-1964.
@article{5238400b0a4b4c0292de6e887e8ec951,
title = "Sodium phenylbutyrate in Huntington's disease: A dose-finding study",
abstract = "Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose-finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose-escalation/de-escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose-response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well-tolerated in human HD.",
keywords = "Histone deacetylase inhibitor, Huntington's disease, Sodium phenylbutyrate",
author = "Hogarth, {Penelope (Penny)} and Luca Lovrecic and Dimitri Krainc",
year = "2007",
month = "10",
day = "15",
doi = "10.1002/mds.21632",
language = "English (US)",
volume = "22",
pages = "1962--1964",
journal = "Movement Disorders",
issn = "0885-3185",
publisher = "John Wiley and Sons Inc.",
number = "13",

}

TY - JOUR

T1 - Sodium phenylbutyrate in Huntington's disease

T2 - A dose-finding study

AU - Hogarth, Penelope (Penny)

AU - Lovrecic, Luca

AU - Krainc, Dimitri

PY - 2007/10/15

Y1 - 2007/10/15

N2 - Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose-finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose-escalation/de-escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose-response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well-tolerated in human HD.

AB - Transcriptional dysregulation in Huntington's disease (HD) is mediated in part by aberrant patterns of histone acetylation. We performed a dose-finding study in human HD of sodium phenylbutyrate (SPB), a histone deacetylase inhibitor that ameliorates the HD phenotype in animal models. We used a dose-escalation/de-escalation design, using prespecified toxicity criteria and standard clinical and laboratory safety measures. The maximum tolerated dose was 15 g/day. At higher doses, toxicity included vomiting, lightheadedness, confusion, and gait instability. We saw no significant laboratory or electrocardiographic abnormalities. Gene expression changes in blood suggested an inverse dose-response. In conclusion, SPB at 12 to 15 g/day appears to be safe and well-tolerated in human HD.

KW - Histone deacetylase inhibitor

KW - Huntington's disease

KW - Sodium phenylbutyrate

UR - http://www.scopus.com/inward/record.url?scp=36248970599&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36248970599&partnerID=8YFLogxK

U2 - 10.1002/mds.21632

DO - 10.1002/mds.21632

M3 - Article

C2 - 17702032

AN - SCOPUS:36248970599

VL - 22

SP - 1962

EP - 1964

JO - Movement Disorders

JF - Movement Disorders

SN - 0885-3185

IS - 13

ER -